Oligog cf-5/20 - 17.5 mg    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
299嚢胞性線維症1

299. 嚢胞性線維症 [臨床試験数:1,592,薬物数:1,539(DrugBank:255),標的遺伝子数:81,標的パスウェイ数:162
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 1,592 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-000378-30-GB
(EUCTR)
03/03/202026/06/2019A dose finding study of OligoG in patients with CF.A randomised, double-blind, dose finding study of inhaled alginate oligosaccharide (OligoG) vs placebo in patients with Cystic Fibrosis (CF). Cystic Fibrosis
MedDRA version: 20.0;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: OligoG CF-5/20 - 17.5 mg
INN or Proposed INN: OLIGOG CF-5/20
Other descriptive name: OLIGOG CF-5/20
Product Name: OligoG CF/20 - 27.5 mg
INN or Proposed INN: OLIGOG CF-5/20
Other descriptive name: OLIGOG CF-5/20
Product Name: OligoG CF/20 - 37.5 mg
INN or Proposed INN: OLIGOG CF-5/20
Other descriptive name: OLIGOG CF-5/20
AlgiPharma ASNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
168Phase 2Poland;Ireland;Austria;Germany;United Kingdom